UB Paderborn / Katalog / Suche / in CDI

CA-049: Sulfamides hypoglycémiants(SU) en 2e ligne associés à un risque accru de maladie cardiovasculaire, de mortalité toutes causes et d'hypoglycémie sévère vs Inhibiteurs – DPP4 (iDPP4)

Diabetes & metabolism, 2016-03, Vol.42, p.A48-A48

2016

Volltextzugriff (PDF)

Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study

European journal of vascular and endovascular surgery, 2017-10, Vol.54 (4), p.480-486

2017

Volltextzugriff (PDF)

Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study

Journal of hepatology, 2015-08, Vol.63 (2), p.456-461

2015

Volltextzugriff (PDF)

Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting

International journal of chronic obstructive pulmonary disease, 2020-01, Vol.15, p.235-245

2020

Volltextzugriff (PDF)

Myocardial infarction and peripheral arterial disease: Treatment patterns and long-term outcome in men and women results from a Swedish nationwide study

European journal of preventive cardiology, 2021, Vol.28 (13), p.1426

2021

Volltextzugriff (PDF)

Editor's Choice – Effect of More Expedited Carotid Intervention on Recurrent Ischaemic Event Rate: A National Audit

European journal of vascular and endovascular surgery, 2018-10, Vol.56 (4), p.467-474

2018

Volltextzugriff (PDF)

Factors associated with lung cancer in COPD patients

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.1833-1839

2018

Volltextzugriff (PDF)

SGLT2i vs bolus insulin as add-on to stable basal insulin treatment in type 2 diabetes and risk of cardiovascular disease and mortality: a nationwide observational study

DIABETOLOGIA, 2018, Vol.61, p.S58

2018

Volltextzugriff (PDF)

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

European heart journal, 2015-05, Vol.36 (19), p.1163-1170

2015

Volltextzugriff (PDF)

P38 PATIENT‐REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

HemaSphere, 2023-05, Vol.7 (S2), p.32-32

2023

Volltextzugriff (PDF)

Total cost of health care resource utilization for asthma patients in Sweden with different exposures to oral corticosteroids

ALLERGY, 2018, Vol.73 (Suppl.105), p.529

2018

Volltextzugriff (PDF)

2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA

European journal of cancer (1990), 2015-09, Vol.51, p.S477-S477

2015

Volltextzugriff (PDF)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

HemaSphere, 2023-05, Vol.7 (S2), p.29-30

2023

Volltextzugriff (PDF)

Second-line treatment with sulfonylurea compared to DPP4 inhibitors is associated with risk of cardiovascular disease, all-cause mortality and severe hypoglycaemia

DIABETOLOGIA, 2015, Vol.58 (Suppl. 1), p.S64

2015

Volltextzugriff (PDF)

First-line and intensified treatment with glucose lowering drugs in the Swedish type 2 diabetes population

DIABETOLOGIA, 2015, Vol.58 (Suppl. 1), p.S181

2015

Volltextzugriff (PDF)

Second-line treatment with sulfonylurea compared to DPP4 inhibitors demonstrated associations with earlier treatment intensification with insulin

DIABETOLOGIA, 2015, Vol.58 (Suppl. 1), p.S189

2015

Volltextzugriff (PDF)

Patient characteristics, treatment and prevalence/incidence of the type 2 diabetes population in Sweden: a nationwide study from 2006 to 2013

DIABETOLOGIA, 2015, Vol.58, p.S180

2015

Volltextzugriff (PDF)

Dapagliflozin compared to DPP4i treatment is associated with lower risk of kidney disease, heart failure and all-cause death: CVD-REAL Nordic

DIABETOLOGIA, 2017, Vol.60 (S1), p.S401

2017

Volltextzugriff (PDF)

Low‐dose acetylsalicylic acid and gastrointestinal ulcers or bleeding – a cohort study of the effects of proton pump inhibitor use patterns

Journal of internal medicine, 2013-10, Vol.274 (4), p.371-380

2013

Volltextzugriff (PDF)

Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE)

International journal of clinical practice (Esher), 2015-10, Vol.69 (10), p.1171-1178

2015

Volltextzugriff (PDF)

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients

Journal of human hypertension, 2014-11, Vol.28 (11), p.663-669

2014

Volltextzugriff (PDF)

Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)

European journal of heart failure, 2021-09, Vol.23 (9), p.1499-1511

2021

Volltextzugriff (PDF)

Factors of importance for patients' decision time in acute coronary syndrome

International journal of cardiology, 2010, Vol.141 (3), p.236-242

2010

Volltextzugriff (PDF)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Circulation (New York, N.Y.), 2017-07, Vol.136 (3), p.249-259

2017

Volltextzugriff (PDF)

Long-Term Healthcare Costs of Patients with Symptomatic Peripheral Artery Disease with and without a History of Atherosclerotic Disease: Results from a Swedish Nationwide Study

Value in health, 2016, Vol.19 (7), p.A608-A609

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

CA-049: Sulfamides hypoglycémiants(SU) en 2e ligne associés à un risque accru de maladie cardiovasculaire, de mortalité toutes causes et d'hypoglycémie sévère vs Inhibiteurs – DPP4 (iDPP4)

Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study

Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study

Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting

Myocardial infarction and peripheral arterial disease: Treatment patterns and long-term outcome in men and women results from a Swedish nationwide study

Editor's Choice – Effect of More Expedited Carotid Intervention on Recurrent Ischaemic Event Rate: A National Audit

Factors associated with lung cancer in COPD patients

SGLT2i vs bolus insulin as add-on to stable basal insulin treatment in type 2 diabetes and risk of cardiovascular disease and mortality: a nationwide observational study

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

P38 PATIENT‐REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

Total cost of health care resource utilization for asthma patients in Sweden with different exposures to oral corticosteroids

2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

Second-line treatment with sulfonylurea compared to DPP4 inhibitors is associated with risk of cardiovascular disease, all-cause mortality and severe hypoglycaemia

First-line and intensified treatment with glucose lowering drugs in the Swedish type 2 diabetes population

Second-line treatment with sulfonylurea compared to DPP4 inhibitors demonstrated associations with earlier treatment intensification with insulin

Patient characteristics, treatment and prevalence/incidence of the type 2 diabetes population in Sweden: a nationwide study from 2006 to 2013

Dapagliflozin compared to DPP4i treatment is associated with lower risk of kidney disease, heart failure and all-cause death: CVD-REAL Nordic

Low‐dose acetylsalicylic acid and gastrointestinal ulcers or bleeding – a cohort study of the effects of proton pump inhibitor use patterns

Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE)

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients

Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)

Factors of importance for patients' decision time in acute coronary syndrome

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Long-Term Healthcare Costs of Patients with Symptomatic Peripheral Artery Disease with and without a History of Atherosclerotic Disease: Results from a Swedish Nationwide Study

Suchergebnisse filtern